Analyst Expects Immediate $70/Share Offer for ImClone (IMCL) from Bristol-Myers Following News
More News related to BMY
- Exelixis and Bristol-Myers Squibb to Co-Develop XL413, a Selective Cdc7 Inhibitor
- Bristol-Myers Squibb to Present at Healthcare Conference
- Tekmira Pharmaceuticals Corporation Announces Third Quarter 2008 Operating Results and Provides Program Update
- Athersys Announces Clinical Development Milestone in Bristol-Myers Squibb Discovery Alliance
- Notable Analyst Rating Changes 11/07: ANF, TWTC, CECEO Upgraded; TM, DLB, SI Downgraded
More News related to GSK
- Citi Downgrades XenoPort (XNPT) to Hold, Slashes Price Target
- Glaxo (GSK) and Theravance (THRX) Announce Positive Results from Phase 2b Study for LABA, '444
- David Moenning's Daily State of the Markets: 11/24
- Dr. Reddy’s (RDY) Launches Generic Imitrex
- Unusual 11 Mid-Day Movers 11/21: DISK, LGND, SOLR, AU Higher; BGP, BHS, FL, MED Lower
More News related to IMCL
- NASDAQ OMX and Leerink Swann to Co-Host Healthcare Industry Forum
- Lilly Completes Cash Tender Offer for ImClone Systems
- ImClone Systems' State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
- Randomized Phase 2 Study of IMC-A12 for HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
- ImClone Systems Announces Clearance of Tender Offer by German Federal Cartel Office
More News related to Rumors
- Sources Say 'Highly Unlikely' That Miller Buys Yahoo! (YHOO) -CNBC
- Reports Former AOL CEO Raising Money For Yahoo! (YHOO) Deal
- Former AOL CEO John Miller In Talks With PE Shops To Buy Yahoo (YHOO)
- Reports Total Is Preparing A Bid For NEXEN (NXY)
- NEXEN (NXY) Pops On Buyout Talk
This morning, ImClone Systems (NASDAQ: IMCL) Chairman Carl Icahn noted that the have determined that the $60 per share offer from Bristol-Myers Squibb Company (NYSE: BMY) is inadequate and said that the company has received a $70 per share acquisition offer from a large pharmaceutical company.
There is speculation that this mystery bidder could be Pfizer Inc. (NYSE: PFE), Merck (NYSE: MRK), Glaxosmithkline plc (NYSE: GSK), Novartis AG (NYSE: NVS) or Eli Lilly (NYSE: LLY).
Commenting on this news, Deutsche Bank said this news will force Bristol-Myers Squibb's hand to offer $70 with no due diligence conditions immediately. They said, "Our best guess, is that BMY winds up acquiring IMCL for $70, and that this is a good strategic and financial deal for BMY at that price."
Shares of ImClone are up 7% to $68 this AM.
Related Categories
Analyst CommentsInsiders' Blog
Mergers and Acquisitions
Rumors
Stocks Mentioned
+0.92Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
